Want to see LRMR full AI Analyst Report?
Top Page
Larimar Therapeutics
(NASDAQ:LRMR)
Select Model
Select Model
Rating:55Neutral
Price Target:
$4.00
▲(0.00% Upside)
Action:Reiterated
Date:08/04/26
The score is held back primarily by weak financial performance (no revenue, widening losses, and substantial cash burn) and limited valuation support due to negative earnings and no dividend. Offsetting these are constructive recent corporate/regulatory milestones toward a rolling BLA and neutral-to-mildly positive technical momentum, which improve the near-term outlook but do not eliminate funding and execution risk.
Positive Factors
Regulatory progress: rolling BLA
FDA alignment on a rolling BLA using skin frataxin as a surrogate and submission of the first module materially reduces regulatory uncertainty and creates a clear, accelerated path to potential approval. This structural milestone increases program de-risking and timelines for commercial planning.
Negative Factors
Pre-revenue with widening losses
The company remains pre-revenue with consistently expanding net losses, reflecting rising R&D and readiness spending. Persistent negative earnings mean long-term value depends entirely on clinical/regulatory success and future commercialization, heightening execution and financing risk for investors.
Read all positive and negative factors
Positive Factors
Negative Factors
Regulatory progress: rolling BLA
FDA alignment on a rolling BLA using skin frataxin as a surrogate and submission of the first module materially reduces regulatory uncertainty and creates a clear, accelerated path to potential approval. This structural milestone increases program de-risking and timelines for commercial planning.
Read all positive factors
Larimar Therapeutics (LRMR) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$396.83M
Dividend YieldN/A
Average Volume (3M)2.47M
Price to Earnings (P/E)―
Beta (1Y)1.64
Revenue GrowthN/A
EPS Growth-39.31%
CountryUS
Employees71
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.99
Shares Outstanding103,882,935
10 Day Avg. Volume1,373,940
30 Day Avg. Volume2,472,096
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)3.56
Price to Sales (P/S)0.00
P/FCF Ratio-2.45
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$12.33Price Target Upside208.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-1.41
Revenue Forecast (FY)N/A
Larimar Therapeutics Business Overview & Revenue Model
Company Description
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology pl...
How the Company Makes Money
As a clinical-stage biotechnology company without approved commercial products, Larimar Therapeutics primarily generates revenue, when applicable, from collaboration and license arrangements (e.g., upfront payments, milestone payments tied to deve...
Larimar Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
20
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -172.30M | -165.32M | -80.29M | -36.64M | -35.04M | -50.31M |
| Net Income | -172.60M | -165.67M | -80.60M | -36.95M | -35.35M | -50.64M |
Balance Sheet | ||||||
| Total Assets | 165.30M | 145.84M | 200.22M | 95.94M | 126.41M | 78.67M |
| Cash, Cash Equivalents and Short-Term Investments | 156.27M | 136.85M | 183.45M | 86.79M | 118.43M | 70.10M |
| Total Debt | 4.96M | 4.07M | 5.12M | 5.55M | 5.41M | 6.00M |
| Total Liabilities | 37.92M | 67.76M | 28.41M | 14.21M | 15.50M | 14.25M |
| Stockholders Equity | 127.38M | 78.08M | 171.81M | 81.72M | 110.90M | 64.41M |
Cash Flow | ||||||
| Free Cash Flow | -156.08M | -113.29M | -71.28M | -33.62M | -27.67M | -42.44M |
| Operating Cash Flow | -155.92M | -113.20M | -70.76M | -33.46M | -27.57M | -42.10M |
| Investing Cash Flow | 55.11M | 100.31M | -85.39M | 33.35M | -90.96M | 24.17M |
| Financing Cash Flow | 172.77M | 65.09M | 161.88M | 30.00K | 75.26M | 19.89M |
Larimar Therapeutics Technical Analysis
Positive
4.00
Price Trends
3.64
Positive
3.99
Positive
3.90
Positive
Market Momentum
0.12
Negative
60.38
Neutral
78.61
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LRMR, the sentiment is Positive. The current price of 4 is above the 20-day moving average (MA) of 3.89, above the 50-day MA of 3.64, and above the 200-day MA of 3.90, indicating a bullish trend. The MACD of 0.12 indicates Negative momentum. The RSI at 60.38 is Neutral, neither overbought nor oversold. The STOCH value of 78.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LRMR.
Larimar Therapeutics Risk Analysis
Larimar Therapeutics disclosed 84 risk factors in its most recent earnings report. Larimar Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Larimar Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
63 Neutral | $856.92M | 9.11 | -54.39% | ― | ― | ― | |
56 Neutral | $733.44M | -10.18 | -60.42% | ― | ― | 26.28% | |
55 Neutral | $396.83M | -1.82 | -137.39% | ― | ― | -39.31% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
45 Neutral | $306.69M | -1.26 | -61.41% | ― | 8.16% | -434.76% | |
44 Neutral | $265.97M | -3.87 | 72.64% | ― | 20.08% | 14.06% | |
43 Neutral | $298.31M | -1.21 | -181.70% | ― | ― | 17.61% |
* Healthcare Sector Average
LRMR
Larimar Therapeutics
4.16
0.38
10.05%
OMER
Omeros
13.25
9.11
220.05%
VNDA
Vanda
5.00
0.81
19.33%
FHTX
Foghorn Therapeutics
6.07
1.36
28.87%
CADL
Candel Therapeutics
10.59
4.38
70.53%
NMRA
Neumora Therapeutics, Inc.
1.63
0.19
13.19%
Larimar Therapeutics Corporate Events
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
Larimar reports Q2 results and nomlabofusp progress
Positive
Aug 4, 2026
On August 4, 2026, Larimar Therapeutics reported its second-quarter 2026 financial and business results, highlighting progress in the development of its lead Friedreich’s ataxia candidate nomlabofusp. Longer-term open-label study data releas...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Larimar Advances Nomlabofusp BLA Toward Accelerated Approval
Positive
Jun 29, 2026
On June 29, 2026, Larimar Therapeutics reported that it has submitted the first module of a rolling Biologics License Application to the U.S. Food and Drug Administration, seeking accelerated approval of its investigational therapy nomlabofusp for...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Larimar Shareholders Approve Governance and Capital Structure Changes
Positive
May 19, 2026
On May 19, 2026, Larimar Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders virtually, where shareholders elected Class III directors Frank Thomas, Carole S. Ben-Maimon, M.D., and Joseph Truitt to serve until the 2029 annual meeting a...
Business Operations and StrategyFinancial DisclosuresPrivate Placements and FinancingRegulatory Filings and Compliance
Larimar Details Q1 Results and Nomlabofusp Regulatory Progress
Positive
May 14, 2026
On May 14, 2026, Larimar Therapeutics reported first-quarter 2026 results and detailed regulatory and clinical progress for nomlabofusp in Friedreich’s ataxia. The company highlighted its intention to begin a rolling biologics license applic...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.